September #63 : Resistance Assistance - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Long Live The Queens

How To Vote

Pills! Chills! Thrills! Spills!

Keeping Up With The Jones

Alabama Bound

Green Alert!

Publisher’s Letter


Double Identity

Say What?

Thespian Avengers

Catching Up With...

Off-Line Service

Data Drill

Hair Comes The Condoms

There’s No Place Like Om

Straight To The Heart


Second Sex First


He’s All That

Recovery Lite

Road Trippin'

Beyond The Valley Of The Dolls

Change of Heart

Crossing the Liver

Warning: Natural Selection

Dandelion Whine

Teen Talk

Skin Deep

Resistance Assistance

Dishes On The Side

Kentucky Woman

Comfort Zone

The Funky Fungus Among Us

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

September 2000

Resistance Assistance

by Tim Horn

Once upon a time, viral load tests confused the hell out of everybody. It wasn’t until official usage guidelines were produced by major medical organizations, such as the International AIDS Society-USA (IAS-USA) and the United States Public Health Service (USPHS), that the cloud of uncertainty began to lift. Now drug-resistance testing, a technological breakthrough that helps determine which drugs may not work against your virus, has many doctors and people with HIV scratching their heads. Luckily, the IAS-USA has just extended a helping hand with resistance-testing guidelines, published in May in the Journal of the American Medical Association (available at

Two types of drug-resistance assays (tests) are available: genotypic, which examines HIV’s genetic structure for mutations (changes) that may lead to drug resistance, and phenotypic, which actually tests the virus’ ability to reproduce in the presence of each approved anti-HIV drug (see “Play It as It Lays,” POZ, January 2000). Usage guidelines were needed, says IAS-USA panelist Martin Hirsch, MD, of Harvard Medical School, “to help caregivers and payers determine when resistance testing is justified.”

According to the IAS-USA, drug-resistance testing should be “considered” for recently infected HIVers to determine if transmission involved a drug-resistant strain of the virus; it is “recommended” for PWAs whose first or subsequent HAART combination is failing, preferably before stopping or switching the faulty regimen.

But which test to take? “We don’t think there are sufficient comparative data to choose between one assay and another at this time,” Hirsch says. “Hopefully, studies underway or planned will provide the necessary information for people with HIV to make informed choices.”

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.